NeoDynamics’ Gets Clearance for New Version of Its Breast Cancer Biopsy Device

NeoDynamics’ updated version of its breast cancer biopsy system, NeoNavia, has received confirmation from the notified body Intertek and has been accepted as an update to the EU-approved version used in clinical studies.

The biopsy system includes three probe options that allow the biopsy to be customized for individual cases. It also offers needle control and targeting precision.

The company is now “finalizing formal verification and validation of the updated system” while accelerating activities before a planned European launch of the updated system in mid-2020, said NeoDynamics CEO Anna Eriksrud.